Difference between revisions of "Lauffenburger:Laura Sontag"

From OpenWetWare
Jump to: navigation, search
m
Line 6: Line 6:
 
[[Image:Laura_Sontag.JPG|150px|right]]
 
[[Image:Laura_Sontag.JPG|150px|right]]
  
'''Laura Sontag''' (Computational and Systems Biology doctoral student), in collaboration with Prof. Peter Sorger (Biology/BE, MIT) and Prof. Tyler Jacks (Biology/Center for Cancer Research,
+
'''Laura Sontag''' (Computational and Systems Biology doctoral student)
MIT)
+
Advisors: Professors Peter Sorger (Biology/BE, MIT) and Doug Lauffenburger (Biology/BE, MIT), in collaboration with Prof. Tyler Jacks (Biology/Center for Cancer Research, MIT)
  
  
Line 13: Line 13:
 
activated by mutations in the K-ras oncogene.  The Ras signaling cascade
 
activated by mutations in the K-ras oncogene.  The Ras signaling cascade
 
constitutes a major pathway shown to be deregulated due to activating
 
constitutes a major pathway shown to be deregulated due to activating
mutations in 30% of all human tumors.  The vast majority of mutations occur in the
+
mutations in 30% of all human tumors.  The vast majority of mutations occur in K-ras.  We use genetically engineered mice that harbor a conditional,
K-ras isoform.  We use genetically engineered mice that harbor a conditional,
 
 
activatable K-ras allele as a model of human cancer.
 
activatable K-ras allele as a model of human cancer.
  

Revision as of 14:31, 5 February 2006

Wikiburger top.jpg

Home        People        Research        Publications        Links        Internal       

Laura Sontag.JPG

Laura Sontag (Computational and Systems Biology doctoral student) Advisors: Professors Peter Sorger (Biology/BE, MIT) and Doug Lauffenburger (Biology/BE, MIT), in collaboration with Prof. Tyler Jacks (Biology/Center for Cancer Research, MIT)


Computational and experimental analysis of mitogenic signaling pathways activated by mutations in the K-ras oncogene. The Ras signaling cascade constitutes a major pathway shown to be deregulated due to activating mutations in 30% of all human tumors. The vast majority of mutations occur in K-ras. We use genetically engineered mice that harbor a conditional, activatable K-ras allele as a model of human cancer.


Email: sontag {AT} mit {DOT} edu

Laura Sontag's Homepage